Parkinson’s Disease Treatment Market Size, Share, Growth Report 2030

The global Parkinson’s disease Treatment market, which is projected at 8.38 (USD Billion) by 2026, is slated to register a CAGR of nearly 7.5% over 2020-2026. The report offers valuation and analysis of Parkinson’s disease Treatment market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2019 along with a forecast from 2020 to 2026 based on value (USD Billion).

Introduction

Parkinson is chronic neurodegenerative disorder that affects the body movements and results in tremor in hands, stiffness in movements of body parts & muscles, bradykinesia, and postural instability. Other symptoms of the disease include depression, dysphagia, emotional changes, constipation, urine problems, dysarthria, disturbed sleep, and skin problems. The disease has notable impact on mobility as well as muscle control of the patients.  Furthermore, the disease is influenced by both motor as well as non-motor characteristics. For instance, motor symptoms of the disease are attributed to loss of striatal dopaminergic neurons and non-motor symptoms of the disorder supports loss of neurons in non-dopaminergic areas of nervous system.

According to NCBI, at present, there are no disease altering therapies for the disease. However, medical management makes use of dopaminergic medicines and deep brain stimulation to treat patients having Parkinson disease. Reportedly, levodopa therapy is the most commonly used for treating Parkinson disorder in early stages and can help in reducing tremor, bradykinesia, and muscle rigidity to a large extent in the patients. Moreover, levodopa is combined with dopa-decarboxylase inhibitor to restrict the side effects like nausea. For the record, dopamine agonists like rotigotine or ropinirole are also popular medicines used for treating Parkinson disease. In addition to this, monoamine oxidase B inhibitors like selegiline and rasagiline as well as catecho-O-Methyltransferase inhibitors like entacapone are utilized for reducing metabolism of dopamine.  Apparently, these therapies have the ability of restoring dopaminergic activities in striatum along with bringing enhancements in motor features of Parkinson disorder.

Market Growth Dynamics

Massive utilization of L-Dopa, a symptomatic dopamine replacement treatment and nigrostriatal system will boost the market trends. In addition to this, the shifting of research activities from symptomatic treatment to Parkinson disorder modifying treatment will create lucrative growth avenues for Parkinson’s disease treatment industry over the forthcoming years. Large-scale research and clinical trials are under way for bringing a revolution in symptomatic treatment of Parkinson’s disease and this can embellish the business growth. Apart from this, vital breakthroughs in development and clinical testing of drugs for providing modification in the Parkinson’s disease are projected to contribute substantially towards the growth of Parkinson’s disease treatment industry over the years to come. Reportedly, cell-based approaches and viral gene-delivery approaches are also the best available alternatives for treating Parkinson Disease and this will help the market reach new horizons of growth within the next couple of years.

Furthermore, ongoing genetic & neuropathological research is predicted to provide new insights into the understanding of the Parkinson disorder and this will enhance the market earnings in the coming decade. Citing an instance, in 1997, a new gene mutation for alpha-synuclein protein causing autosomal dominant Parkinson disorder was discovered. Additionally, use of non-dopaminergic drugs like amantadine and anticholinergic has proved to offer symptomatic relief in early stages of Parkinson disease treatment. Anticholinergic drugs like benztropine and trihexphenidyl are used in young patients impacted due to tremors and these drugs are used along with levodopa.

Additionally, the Braak staging hypothesis that Parkinson disorder begins in either olfactory bulb or gastrointestinal system has paved a way continuum of researchers in the domain of Parkinson disease treatment, thereby driving the growth of the market in the coming years. Furthermore, use of adjunctive therapy and anti-glutamatergic medicines for treating Parkinson disease will proliferate the expansion of the Parkinson’s disease treatment market over the forthcoming years.

Asia Pacific Market To Record Highest Growth Rate Over 2020-2026

The growth of the industry in the sub-continent over the estimated timespan is owing to favorable government policies and surge in the research activities pertaining to the treatment of Parkinson disease in the countries like India, Japan, and China. In addition to this, huge sale of generic medicines and surge in the aging population prone to the Parkinson disorder will further prop up the growth of the Parkinson’s disease market in Asia Pacific zone.

Key players profiled in the report are BIAL Pharm; Novartis AG; Salix Pharmaceuticals; GlaxoSmithKline Plc.; Impax Laboratories, Inc.; Daiichi Sankyo; Wockhardt Limited; Mylan N.V.; Cipla Inc.; Teva Pharmaceutical Industries Ltd.; Par Pharmaceutical; Orion Corporation; and Apotex Inc.

The global Parkinson’s disease treatment market is segmented as follows:

By therapeutic class:

• Dopamine precursors
• Monoamine oxidase B inhibitors (MAO-B inhibitors)
• Catechol-O-methyl transferase (COMT) inhibitors
• Dopamine agonists (non-ergoline)
• Carbidopa/Levodopa
• Other Therapeutic Classes

By medical devices:

• Deep Brain Stimulation (DBS) Devices
• Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices

By patient care setting:

• Clinics
• Hospitals

By distribution channel:

• Online pharmacies
• Retail pharmacies
• Hospital pharmacies
• Drug stores

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa